Search results for Alny

Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare - Slideshow

Allogene: Early ALPHA3 Data Suggests Potential Paradigm Shift For Cema-Cel In LBCL

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line...

ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK, April 7, 2026 /PRNewswire/ --

Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.

Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In

Amylyx (AMLX) Q1 2026 Earnings Transcript

Image source: The Motley Fool. DATEThursday, May 7, 2026 at 8 a.m. ETCALL PARTICIPANTSCo-Chief Executive Officer — Justin KleeCo-Chief Executive Officer — Joshua CohenChief Commer...

Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class

Jefferies raises Allogene stock price target to $10 on trial data

Biogen links up with Alloy platform to boost ASO drug development

The agreement allows Biogen to apply the platform to advance antisense therapeutics against multiple undisclosed targets. Alloy will receive an upfront payment and is eligible for...

ALIT Deadline: ALIT Investors Have Opportunity to Lead Alight, Inc. Securities Fraud Lawsuit

NEW YORK, May 8, 2026 /PRNewswire/ --

Aligos sells China rights to HBV drug to hepatology player Amoytop in $445M deal

Aligos Therapeutics has secured a $25 million upfront fee from hepatology biopharma Amoytop in exchange for the China rights to its phase 2-stage chronic hepatitis B virus (HBV) tr...

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval

This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.

Avalyn Pharma Begins IPO Process For Pulmonary Fibrosis Pipeline

Recursion Pharmaceuticals May Be Losing Ground To Its Peers

Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get

Apellis jumps as Biogen agrees $5.6 Billion acquisition, offering $41/share plus milestones, boosting rare-disease portfolio. Importance Rank: ...

Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform

Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock

Allogene CEO to step down; Agios drug fails key test

David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approv...

Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.

Protalix: Elfabrio Struggles Against Oral Competition

Alumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospects

Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather than pursue the phase 3 program envisaged before it acquir...

Lilly pays AC Immune $12.5M to expand Alzheimer’s collab as asset draws closer to clinic

Eli Lilly has handed AC Immune 10 million Swiss francs ($12.5 million) to expand their Alzheimer’s disease collaboration as a candidate moves closer to the clinic.